Her2 low (but not negative): the newest biomarker on the block for gastro-oesophageal adenocarcinoma
This study is in line with prevalence data from another recent study that showed HER2 low prevalence is approximately 21% in patient with inoperable or metastatic gastric carcinoma.2 Trastuzumab for HER2 overexpression/ HER2 amplification was one of the first target therapies for solid tumour, and it...
Source: Journal of Clinical Pathology - Category: Pathology Authors: Hechtman, J. F. Tags: Editorials Source Type: research
More News: Adenocarcinoma | Cancer & Oncology | Carcinoma | Esophagus Cancer | Gastric (Stomach) Cancer | Gastroenterology | HER2 | Herceptin | Italy Health | Pathology | Study